Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Pleural Effusion, Malignant

Pleural Effusion

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Pleural Diseases

Pleural Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Cisplatin

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks

Cisplatin 30mg by intrapleural given every two weeks

Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week

Cisplatin 30mg,intrapleural administration,each 2 week

Nan Du

To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).

Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer

Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients

Response assessed by type-B ultrasonic tests; Complete remission (CR) was considered when the accumulated fluid had disappeared and was stable for at least four weeks; partial remission (PR) was considered when \>50% of the accumulated fluid had disappeared, symptoms had improved, and the remaining fluid had failed to increase for at least four weeks; The total efficiency ORR was calculated by taking the sum of CR+PR

Roche Pharma AG

Chinese PLA General Hospital

director of oncology department in PLA 304 hospital

Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks

Bevacizumab: Bevacizumab300mg\&Cisplatin 30mg by intrapleural administration of each 2 week

Cisplatin: Cisplatin 30mg,intrapleural administration,Q2W

Bevacizumab & Cisplatin

Cisplatin 30mg by intrapleural given every two weeks

Cisplatin: Cisplatin 30mg,intrapleural administration,Q2W

Total

Age, Categorical

Sex: Female, Male

Dr. Nan Du

Number of Participants With "Complete Response" and "Partial Response"

Median Progression Free Survival (PFS)

Overall Survival (OS)

Adverse Reactions

Qualify of Life (QoL)

Quantitative RT-PCR(Reverse Transcription-Polymerase Chain Reaction) for VEGF-A(Vascular Endothelial Growth Factor A)

Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks

Bevacizumab: Bevacizumab300mg\&Cisplatin 30mg by intrapleural administration of each 2 week

Cisplatin: Cisplatin 30mg,intrapleural administration,each 2 week

Overall Study

Spots Global Cancer Trial Database for intrapleural administration